Chase Knickerbocker
Stock Analyst at Craig-Hallum
(4.74)
# 128
Out of 5,157 analysts
42
Total ratings
65.96%
Success rate
37.59%
Average return
Main Sectors:
Stocks Rated by Chase Knickerbocker
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ETON Eton Pharmaceuticals | Maintains: Buy | $29 → $30 | $17.40 | +72.41% | 7 | Mar 3, 2026 | |
| NRXS NeurAxis | Maintains: Buy | $7 → $8 | $6.31 | +26.78% | 2 | Dec 22, 2025 | |
| HROW Harrow | Maintains: Buy | $54 → $64 | $36.08 | +77.38% | 4 | Sep 23, 2025 | |
| FENC Fennec Pharmaceuticals | Maintains: Buy | $13 → $14 | $7.89 | +77.44% | 6 | Aug 15, 2025 | |
| PYPD PolyPid | Maintains: Buy | $15 → $13 | $4.32 | +200.93% | 2 | Aug 14, 2025 | |
| XERS Xeris Biopharma Holdings | Maintains: Buy | $6.5 → $11 | $5.82 | +89.00% | 2 | Aug 8, 2025 | |
| DMAC DiaMedica Therapeutics | Maintains: Buy | $8 → $11 | $7.95 | +38.36% | 1 | Jul 18, 2025 | |
| BFLY Butterfly Network | Initiates: Buy | $3 | $3.73 | -19.57% | 1 | Jul 1, 2025 | |
| PHAT Phathom Pharmaceuticals | Maintains: Buy | $12 → $17 | $11.11 | +53.02% | 3 | Jun 9, 2025 | |
| MDWD MediWound | Initiates: Buy | $39 | $17.37 | +124.53% | 1 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $8 | $3.70 | +116.22% | 4 | Jan 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 → $21 | $9.37 | +124.12% | 2 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5 → $6 | $4.53 | +32.45% | 2 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $14 → $12 | $4.57 | +162.58% | 2 | Aug 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $7.99 | +25.19% | 1 | Jul 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1 → $1.2 | $0.62 | +94.17% | 2 | Jul 11, 2023 |
Eton Pharmaceuticals
Mar 3, 2026
Maintains: Buy
Price Target: $29 → $30
Current: $17.40
Upside: +72.41%
NeurAxis
Dec 22, 2025
Maintains: Buy
Price Target: $7 → $8
Current: $6.31
Upside: +26.78%
Harrow
Sep 23, 2025
Maintains: Buy
Price Target: $54 → $64
Current: $36.08
Upside: +77.38%
Fennec Pharmaceuticals
Aug 15, 2025
Maintains: Buy
Price Target: $13 → $14
Current: $7.89
Upside: +77.44%
PolyPid
Aug 14, 2025
Maintains: Buy
Price Target: $15 → $13
Current: $4.32
Upside: +200.93%
Xeris Biopharma Holdings
Aug 8, 2025
Maintains: Buy
Price Target: $6.5 → $11
Current: $5.82
Upside: +89.00%
DiaMedica Therapeutics
Jul 18, 2025
Maintains: Buy
Price Target: $8 → $11
Current: $7.95
Upside: +38.36%
Butterfly Network
Jul 1, 2025
Initiates: Buy
Price Target: $3
Current: $3.73
Upside: -19.57%
Phathom Pharmaceuticals
Jun 9, 2025
Maintains: Buy
Price Target: $12 → $17
Current: $11.11
Upside: +53.02%
MediWound
Feb 28, 2025
Initiates: Buy
Price Target: $39
Current: $17.37
Upside: +124.53%
Jan 22, 2025
Maintains: Buy
Price Target: $10 → $8
Current: $3.70
Upside: +116.22%
Jan 17, 2025
Maintains: Buy
Price Target: $18 → $21
Current: $9.37
Upside: +124.12%
Jan 17, 2025
Maintains: Buy
Price Target: $5 → $6
Current: $4.53
Upside: +32.45%
Aug 1, 2024
Maintains: Buy
Price Target: $14 → $12
Current: $4.57
Upside: +162.58%
Jul 11, 2024
Initiates: Buy
Price Target: $10
Current: $7.99
Upside: +25.19%
Jul 11, 2023
Maintains: Buy
Price Target: $1 → $1.2
Current: $0.62
Upside: +94.17%